Spark gene therapy drug priced less than expected at $850,000

In this video

Share

Spark gene therapy drug priced less than expected at $850,000

CNBC's Meg Tirrell reports Spark Therapeutics' Luxturna, which treats an inherited form of vision loss, will come to market under $1 million.
01:45
Wed, Jan 3 20188:34 AM EST